We are excited to announce this new webcast on diagnosis, risk stratification, and current and emerging therapies for Waldenström's Macroglobulinemia (WM).

Given its rarity, there are comparatively few large-scale phase 3 trials in patients with WM; as a result, WM treatment guidelines and best practices have developed largely in the absence of substantial clinical trial evidence. Thus, real-world data provides a particularly valuable source of information for evaluating the comparative benefits, toxicities, and costs of therapeutic approaches to WM, complementing available clinical trial data and the latest guideline recommendations.

This webcast aims to fill the gaps surrounding the WM disease state and its evolving therapeutic armamentarium in order to accurately identify and stratify patients with WM and make informed decisions surrounding treatment selection, sequencing, and monitoring.

Richard R. Furman, MD
Weill Cornell Medicine
New York, New York

Steven P. Treon, MD, PhD, FACP, FRCP
Dana-Farber Cancer Institute
Harvard University
Boston, Massachusetts


We hope that you find this information relevant to your practice.


Imedex, an HMP Company

NACCME, an HMP Company